Relative Value

The Relative Value of one UCB stock under the Base Case scenario is hidden EUR. Compared to the current market price of 252.5 EUR, Ucb SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

UCB Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
24
Median 3Y
4.7
Median 5Y
3.2
Industry
2.6
Forward
6.5
vs History
34
vs Industry
14
Median 3Y
37
Median 5Y
31.7
Industry
21.4
Forward
31.1
vs History
11
vs Industry
16
Median 3Y
24.7
Median 5Y
15.1
Industry
16.4
vs History
28
vs Industry
9
Median 3Y
47.2
Median 5Y
33.2
Industry
22.8
vs History
0
vs Industry
22
Median 3Y
3
Median 5Y
2.2
Industry
2.2
vs History
0
vs Industry
22
Median 3Y
5
Median 5Y
3.4
Industry
2.9
Forward
6.7
vs History
3
vs Industry
27
Median 3Y
7.2
Median 5Y
4.8
Industry
5.5
vs History
22
vs Industry
16
Median 3Y
18.7
Median 5Y
13.5
Industry
13
Forward
21.6
vs History
38
vs Industry
10
Median 3Y
35.8
Median 5Y
24.3
Industry
16.5
Forward
29.6
vs History
14
vs Industry
15
Median 3Y
25.5
Median 5Y
17
Industry
15.6
vs History
17
vs Industry
13
Median 3Y
36.4
Median 5Y
25.4
Industry
18.7
vs History
0
vs Industry
26
Median 3Y
2.3
Median 5Y
1.9
Industry
1.9

Multiples Across Competitors

UCB Competitors Multiples
Ucb SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Ucb SA
XBRU:UCB
48B EUR 7 36 19.9 26.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.4 56.2 37.8 40.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
271B CHF 4.4 28.7 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
221.1B GBP 5.1 31.6 108.9 159.3
US
Merck & Co Inc
NYSE:MRK
278.1B USD 4.3 14.6 10.3 12.3
CH
Novartis AG
SIX:NOVN
218.9B CHF 4.9 19 12 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.5 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.3B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
BE
Ucb SA
XBRU:UCB
Average P/E: 26.4
36
34%
1.1
US
Eli Lilly and Co
NYSE:LLY
56.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBITDA: 401.9
19.9
33%
0.6
US
Eli Lilly and Co
NYSE:LLY
37.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBIT: 1 715
26.8
52%
0.5
US
Eli Lilly and Co
NYSE:LLY
40.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.3
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5